Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice

Michael E. Burleigh, Vladimir R. Babaev, John A. Oates, Raymond C. Harris, Shiva Gautam, Denis Riendeau, Lawrence J. Marnett, Jason D. Morrow, Sergio Fazio, MacRae F. Linton

Research output: Contribution to journalArticle

269 Citations (Scopus)

Abstract

Background - Atherosclerosis has features of an inflammatory disease. Because cyclooxygenase (COX)-2 is expressed in atherosclerotic lesions and promotes inflammation, we tested the hypotheses that selective COX-2 inhibition would reduce early lesion formation in LDL receptor-deficient (LDLR-/-) mice and that macrophage COX-2 expression contributes to atherogenesis in LDLR-/- mice. Methods and Results - Treatment of male LDLR-/- mice fed the Western diet with rofecoxib or indomethacin for 6 weeks resulted in significant reductions in atherosclerosis in the proximal aorta (25% and 37%) and in the aorta en face (58% and 57%), respectively. Rofecoxib treatment did not inhibit platelet thromboxane production, a COX-1-mediated process, but it significantly reduced the urinary prostacyclin metabolite 2,3-dinor-6-keto-PGF. Fetal liver cell transplantation was used to generate LDLR-/- mice null for expression of the COX-2 gene by macrophages. After 8 weeks on the Western diet, COX-2-/-→LDLR-/- mice developed significantly less (33% to 39%) atherosclerosis than control COX-2+/+→LDLR-/- mice. In both the inhibitor studies and the transplant studies, serum lipids did not differ significantly between groups. Conclusions - The present studies provide strong pharmacological and genetic evidence that COX-2 promotes early atherosclerotic lesion formation in LDLR-/- mice in vivo. These results support the potential of anti-inflammatory approaches to the prevention of atherosclerosis.

Original languageEnglish (US)
Pages (from-to)1816-1823
Number of pages8
JournalCirculation
Volume105
Issue number15
DOIs
StatePublished - Apr 16 2002
Externally publishedYes

Fingerprint

LDL Receptors
Cyclooxygenase 2
Atherosclerosis
Aorta
Macrophages
Cyclooxygenase 1
Thromboxanes
Cell Transplantation
Epoprostenol
Indomethacin
Liver Transplantation
Anti-Inflammatory Agents
Blood Platelets
Pharmacology
Inflammation
Transplants
Lipids
Therapeutics
Serum
Genes

Keywords

  • Atherosclerosis
  • Inflammation
  • Macrophage
  • Mice
  • Transplantation

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Burleigh, M. E., Babaev, V. R., Oates, J. A., Harris, R. C., Gautam, S., Riendeau, D., ... Linton, M. F. (2002). Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation, 105(15), 1816-1823. https://doi.org/10.1161/01.CIR.0000014927.74465.7F

Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. / Burleigh, Michael E.; Babaev, Vladimir R.; Oates, John A.; Harris, Raymond C.; Gautam, Shiva; Riendeau, Denis; Marnett, Lawrence J.; Morrow, Jason D.; Fazio, Sergio; Linton, MacRae F.

In: Circulation, Vol. 105, No. 15, 16.04.2002, p. 1816-1823.

Research output: Contribution to journalArticle

Burleigh, ME, Babaev, VR, Oates, JA, Harris, RC, Gautam, S, Riendeau, D, Marnett, LJ, Morrow, JD, Fazio, S & Linton, MF 2002, 'Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice', Circulation, vol. 105, no. 15, pp. 1816-1823. https://doi.org/10.1161/01.CIR.0000014927.74465.7F
Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002 Apr 16;105(15):1816-1823. https://doi.org/10.1161/01.CIR.0000014927.74465.7F
Burleigh, Michael E. ; Babaev, Vladimir R. ; Oates, John A. ; Harris, Raymond C. ; Gautam, Shiva ; Riendeau, Denis ; Marnett, Lawrence J. ; Morrow, Jason D. ; Fazio, Sergio ; Linton, MacRae F. / Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. In: Circulation. 2002 ; Vol. 105, No. 15. pp. 1816-1823.
@article{a49a1728ffa64224be6af5143ac5a756,
title = "Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice",
abstract = "Background - Atherosclerosis has features of an inflammatory disease. Because cyclooxygenase (COX)-2 is expressed in atherosclerotic lesions and promotes inflammation, we tested the hypotheses that selective COX-2 inhibition would reduce early lesion formation in LDL receptor-deficient (LDLR-/-) mice and that macrophage COX-2 expression contributes to atherogenesis in LDLR-/- mice. Methods and Results - Treatment of male LDLR-/- mice fed the Western diet with rofecoxib or indomethacin for 6 weeks resulted in significant reductions in atherosclerosis in the proximal aorta (25{\%} and 37{\%}) and in the aorta en face (58{\%} and 57{\%}), respectively. Rofecoxib treatment did not inhibit platelet thromboxane production, a COX-1-mediated process, but it significantly reduced the urinary prostacyclin metabolite 2,3-dinor-6-keto-PGF1α. Fetal liver cell transplantation was used to generate LDLR-/- mice null for expression of the COX-2 gene by macrophages. After 8 weeks on the Western diet, COX-2-/-→LDLR-/- mice developed significantly less (33{\%} to 39{\%}) atherosclerosis than control COX-2+/+→LDLR-/- mice. In both the inhibitor studies and the transplant studies, serum lipids did not differ significantly between groups. Conclusions - The present studies provide strong pharmacological and genetic evidence that COX-2 promotes early atherosclerotic lesion formation in LDLR-/- mice in vivo. These results support the potential of anti-inflammatory approaches to the prevention of atherosclerosis.",
keywords = "Atherosclerosis, Inflammation, Macrophage, Mice, Transplantation",
author = "Burleigh, {Michael E.} and Babaev, {Vladimir R.} and Oates, {John A.} and Harris, {Raymond C.} and Shiva Gautam and Denis Riendeau and Marnett, {Lawrence J.} and Morrow, {Jason D.} and Sergio Fazio and Linton, {MacRae F.}",
year = "2002",
month = "4",
day = "16",
doi = "10.1161/01.CIR.0000014927.74465.7F",
language = "English (US)",
volume = "105",
pages = "1816--1823",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "15",

}

TY - JOUR

T1 - Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice

AU - Burleigh, Michael E.

AU - Babaev, Vladimir R.

AU - Oates, John A.

AU - Harris, Raymond C.

AU - Gautam, Shiva

AU - Riendeau, Denis

AU - Marnett, Lawrence J.

AU - Morrow, Jason D.

AU - Fazio, Sergio

AU - Linton, MacRae F.

PY - 2002/4/16

Y1 - 2002/4/16

N2 - Background - Atherosclerosis has features of an inflammatory disease. Because cyclooxygenase (COX)-2 is expressed in atherosclerotic lesions and promotes inflammation, we tested the hypotheses that selective COX-2 inhibition would reduce early lesion formation in LDL receptor-deficient (LDLR-/-) mice and that macrophage COX-2 expression contributes to atherogenesis in LDLR-/- mice. Methods and Results - Treatment of male LDLR-/- mice fed the Western diet with rofecoxib or indomethacin for 6 weeks resulted in significant reductions in atherosclerosis in the proximal aorta (25% and 37%) and in the aorta en face (58% and 57%), respectively. Rofecoxib treatment did not inhibit platelet thromboxane production, a COX-1-mediated process, but it significantly reduced the urinary prostacyclin metabolite 2,3-dinor-6-keto-PGF1α. Fetal liver cell transplantation was used to generate LDLR-/- mice null for expression of the COX-2 gene by macrophages. After 8 weeks on the Western diet, COX-2-/-→LDLR-/- mice developed significantly less (33% to 39%) atherosclerosis than control COX-2+/+→LDLR-/- mice. In both the inhibitor studies and the transplant studies, serum lipids did not differ significantly between groups. Conclusions - The present studies provide strong pharmacological and genetic evidence that COX-2 promotes early atherosclerotic lesion formation in LDLR-/- mice in vivo. These results support the potential of anti-inflammatory approaches to the prevention of atherosclerosis.

AB - Background - Atherosclerosis has features of an inflammatory disease. Because cyclooxygenase (COX)-2 is expressed in atherosclerotic lesions and promotes inflammation, we tested the hypotheses that selective COX-2 inhibition would reduce early lesion formation in LDL receptor-deficient (LDLR-/-) mice and that macrophage COX-2 expression contributes to atherogenesis in LDLR-/- mice. Methods and Results - Treatment of male LDLR-/- mice fed the Western diet with rofecoxib or indomethacin for 6 weeks resulted in significant reductions in atherosclerosis in the proximal aorta (25% and 37%) and in the aorta en face (58% and 57%), respectively. Rofecoxib treatment did not inhibit platelet thromboxane production, a COX-1-mediated process, but it significantly reduced the urinary prostacyclin metabolite 2,3-dinor-6-keto-PGF1α. Fetal liver cell transplantation was used to generate LDLR-/- mice null for expression of the COX-2 gene by macrophages. After 8 weeks on the Western diet, COX-2-/-→LDLR-/- mice developed significantly less (33% to 39%) atherosclerosis than control COX-2+/+→LDLR-/- mice. In both the inhibitor studies and the transplant studies, serum lipids did not differ significantly between groups. Conclusions - The present studies provide strong pharmacological and genetic evidence that COX-2 promotes early atherosclerotic lesion formation in LDLR-/- mice in vivo. These results support the potential of anti-inflammatory approaches to the prevention of atherosclerosis.

KW - Atherosclerosis

KW - Inflammation

KW - Macrophage

KW - Mice

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0037117652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037117652&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000014927.74465.7F

DO - 10.1161/01.CIR.0000014927.74465.7F

M3 - Article

C2 - 11956125

AN - SCOPUS:0037117652

VL - 105

SP - 1816

EP - 1823

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 15

ER -